Eden Radioisotopes Seeks NRC Permit for Domestic Medical Isotope Production Facility

Eden Radioisotopes Moves Forward with NRC Permit Application

Eden Radioisotopes, LLC has officially filed a Construction Permit Application with the U.S. Nuclear Regulatory Commission (NRC) to establish a state-of-the-art isotope production facility near Eunice, New Mexico. This initiative represents a significant step towards creating a domestic source of vital medical isotopes, which are currently not produced at sufficient scale in the United States.

Addressing a Critical Healthcare Need

The facility, once approved, is expected to fulfill up to 50% of the global demand for Molybdenum-99 (Mo-99), a crucial medical isotope involved in over 40,000 diagnostic imaging procedures across the U.S. every day. Furthermore, it will be capable of producing more than 3.5 million doses annually of Lutetium-177 (Lu-177), a form of treatment for various advanced cancers. Currently, the U.S. relies on imports for 100% of its Mo-99 supply, which is sourced from aging foreign reactors. Due to the short half-life of medical isotopes, any disruptions in supply chains can lead to immediate cancellations of scheduled patient procedures, highlighting the urgent need for reliable domestic production.

Legislative Support and Industry Challenges

The pressing situation regarding the U.S. supply of medical isotopes has garnered significant attention from federal lawmakers. The passage of the American Medical Isotope Production Act in 2012 aimed to facilitate the establishment of a dependable domestic supply of isotopes. However, over a decade later, the U.S. still struggles with inadequate production capabilities for both diagnostic and therapeutic isotopes.

"For decades, the American medical system has operated at the mercy of a fragile, foreign-dependent supply chain," stated Carrie Freeman, CEO of Eden Radioisotopes. Freeman emphasized the transformative impact that the Eden facility will have, promising to reshore isotope production essential for fighting diseases like cancer and heart disease.

Innovative Technology Driving Production

Eden’s approach incorporates an "all-target" reactor design that has been exclusively licensed from Sandia National Laboratories. This technology is optimized to maximize isotope production while generating no spent fuel. By integrating a processing facility onsite, Eden aims to enhance the availability of isotopes for U.S. patients. Moreover, the company's efficient facility design and its strategic location in southeastern New Mexico are intended to ensure long-term commercial viability.

The permit application is timely as the NRC rolls out reforms aimed at expediting the licensing processes for advanced reactors. This initiative is fueled by the ADVANCE Act of 2024 and Executive Order 14300, which are designed to streamline regulatory pathways for non-power reactors, thereby fostering a more favorable landscape for new developments in nuclear technology.

Confidence in Regulatory Review Process

Eden Radioisotopes has engaged with regulatory bodies early in the process, and its design is characterized by an inherently safe operational framework. Jim Saldarini, the licensing director at Eden, expressed optimism regarding the NRC's 12-month review timeline, stating that such an assurance is likely to be beneficial for investors, partners, and patients eagerly awaiting the scale-up of domestic production.

Freeman reinforced that the ongoing U.S. nuclear renaissance focuses not only on generating power but also on utilizing nuclear technology to save lives directly. The application for the NRC permit is thus deemed critically important, as it represents a dual opportunity: to safeguard patient health and to reinforce national supply chains in medical isotope production.

Conclusion

Eden Radioisotopes, LLC is setting the groundwork for a transformative project that aims to redefine the medical isotope landscape in the U.S. By reducing dependency on international sources and enhancing domestic production capabilities, the Eden facility stands to be a cornerstone in improving the reliability of critical medical services across the nation, ultimately benefiting countless patients nationwide.